logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Sage Therapeutics, Inc.


USPTO Granted Patents = 99



Trademarks = 11

Forward Citations = 935

Loading Chart...
Loading Chart...

27 inventors (with patents filed for the assignee):

goldMedal Francesco Gerald Salituro (85 out of 184 patents)

silverMedal Albert Jean Robichaud (77 out of 111 patents)

bronzeMedal Boyd Lynn Harrison (67 out of 98 patents)

4.  Gabriel Martinez Botella (66 out of 99 patents)

5.  Maria Jesus Blanco-Pillado (16 out of 16 patents)

6.  Richard Thomas Beresis (15 out of 27 patents)

7.  Andrew Mark Griffin (14 out of 37 patents)

8.  Marshall Lee Morningstar (11 out of 11 patents)

9.  Stephen Jay Kanes (7 out of 7 patents)

10.  Daniel La (7 out of 24 patents)

11.  John Gregory Reid (5 out of 20 patents)

12.  Kiran Reddy (3 out of 25 patents)

13.  Paul Steven Watson (3 out of 23 patents)

14.  Bret Berner (3 out of 65 patents)

15.  Jian Wang (3 out of 5 patents)


Core Competencies:
Neuroactive Steroids
CNS Disorders
Oxysterols
Compositions
Methods of Use
Crystalline Steroids
Epilepsy Treatment
Substituted Steroids
Formulations

99 patents:

1. 12686700 - Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders (2026-07-21),
2. 12673970 - Neuroactive steroids and their methods of use (2026-07-07),
3. 12655175 - C17, C20, and C21 substituted neuroactive steroids and their methods of use (2026-06-16),
4. 12617814 - Neuroactive steroids and methods of use thereof (2026-05-05),
5. 12552829 - Compositions and methods for treating CNS disorders (2026-02-17),
6. 12540157 - Oxysterols and methods of use thereof (2026-02-03),
7. 12534495 - Compositions and methods for treating CNS disorders (2026-01-27),
8. 12473327 - Neuroactive steroids, compositions and uses thereof (2025-11-18),
9. 12448409 - Oxysterols and methods of use thereof (2025-10-21),
10. 12421275 - Compositions and methods for treating CNS disorders (2025-09-23),
11. 12410210 - Neuroactive steroids and their methods of use (2025-09-09),
12. 12358942 - Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid (2025-07-15),
13. 12331070 - C7 substituted oxysterols and methods of use thereof (2025-06-17),
14. 12268697 - Oxysterols and methods of use thereof (2025-04-08),
15. 12264177 - Neuroactive steroids and their methods of use (2025-04-01),
Company Overview
Sage Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, MA, focused on developing innovative therapies for central nervous system (CNS) disorders. The company specializes in neuroactive steroids and oxysterols, aiming to address conditions such as epilepsy and other CNS-related ailments. Sage's research encompasses various compositions and methods of use, emphasizing the potential of crystalline and substituted steroids in therapeutic applications, thereby advancing treatment options for patients with complex neurological conditions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Sage Therapeutics, Inc. USPTO Patent Assignee Logo
99 Patents

#29 in Cambridge, MA

#210 in Massachusetts

#3,825 in US

#7,847 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Sage Therapeutics, Inc.

Forward Citations = 935

27 inventors:

goldMedal Francesco Gerald Salituro (85 out of 184 patents)

silverMedal Albert Jean Robichaud (77 out of 111 patents)

bronzeMedal Boyd Lynn Harrison (67 out of 98 patents)

4.  Gabriel Martinez Botella (66 out of 99 patents)

5.  Maria Jesus Blanco-Pillado (16 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sage Therapeutics, Inc.. Retrieved from https://idiyas.com/company/sage-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…